Sinem Özyılmaz

Dr. Sinem Özyılmaz

Medical Faculty of Istanbul Aydin University, Department in Cardiology
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2020 in Medicina
Verified
Journal Article
Open access
PDF file
SÖSinem Özyılmaz
Sinem Özyılmaz
EAEsra Ergun Alis
Esra Ergun Alis
EEEmrah Ermiş
Emrah Ermiş
SASamir Allahverdiyev
Samir Allahverdiyev
HUHakan Uçar
Hakan Uçar
Background and Objectives: This study aimed to evaluate the relationship between mortality and cardiac laboratory findings in patients who were hospitalized after a positive PCR for COVID-19 infection. Materials and Methods: This study included patients who were admitted to or referred to the hospital between 20 March and 20 June 2020, diagnosed with COVID-19 via a positive RT-PCR from nasal and pharyngeal swab samples. The troponin I level was measured from each patient. Medical records of patients were retrospectively reviewed and analyzed. Results: A hundred and five patients who were diagnosed with COVID-19 and hospitalized, or who died in the hospital due to COVID-19, were included in this study. There was a statistically significant difference between the troponin I high and low level groups in terms of age (years), BMI, shortness of breath (SB), oxygen saturation (%), hypertension, length of stay in the ICU; and for mortality, C-reactive protein, the neutrophil-to-lymphocyte ratio, hemoglobin, lactate dehydrogenase, ferritin, D-dimer, creatine kinase-MB, prothrombin time, calcium, and 25-hydroxy vitamin 25(OH)D3 (all p < 0.05). In the logistic analyses, a significant association was noted between troponin I and the adjusted risk of mortality. A ROC curve analysis identified troponin I values > 7.8 pg/mL as an effective cut-off point in mortality for patients with COVID-19. A troponin I value of higher than 7.8 pg/mL yielded a sensitivity of 78% and a specificity of 86%. Conclusions: The hospital mortality rate was higher among patients diagnosed with COVID-19 accompanied by troponin levels higher than 7.8 pg/mL. Therefore, in patients diagnosed with COVID-19, elevated troponin I levels >7.8 pg/mL can be considered an independent risk factor for mortality.

1 January 2017 in The Anatolian Journal of Cardiology
Verified
Journal Article
Open access
SÖSinem Özyılmaz
Sinem Özyılmaz
It has been shown that the presence of fragmented QRS (fQRS) is associated with poor prognosis in many cardiovascular diseases and in patients with hypertrophic cardiomyopathy (HCM). However, no study has shown an association with the absolute risk score of sudden cardiac death. The aim of this study was to determine the relationship between QRS and the predicted risk score of sudden cardiac death at 5 years (HCM Risk-SCD) in HCM patients. In total, 115 consecutive HCM patients were included in this prospective observational study. The patients were divided into two groups according to the presence [fQRS(+) group (n=65)] or absence [fQRS(-) group (n=50)] of fQRS on a 12-lead electrocardiogram (ECG). The HCM Risk-SCD (%) HCM Risk-SCD (>6%) values and some echocardiographic parameters, including ventricular extrasystole, ventricular tachycardia, cardiopulmonary resuscitation, implantable cardioverter defibrillator implantation, appropriate shock, and heart failure at the time of admission, were significantly higher in the fQRS(+) group than in the fQRS(-) group (all p4 was identified as an effective cut-off point in fQRS for HCM. An HCM Risk-SCD value of >4 yielded a sensitivity of 77% and a specificity of 76%. fQRS is determined to be an independent high-risk indicator of HCM Risk-SCD. It seems to be associated with increased ventricular arrhythmias and some echocardiographic parameters.

1 January 2020 in Archives of Medical Science
Verified
Journal Article
Open access
HPHamdi Pusuroglu
Hamdi Pusuroglu
USUmut Somuncu
Umut Somuncu
IBIsmail Bolat
Ismail Bolat
OAOzgur Akgul
Ozgur Akgul
HYHayriye Ak Yıldırım
Hayriye Ak Yıldırım
AYAydın Yıldırım
Aydın Yıldırım
Introduction Obstructive sleep apnea (OSA) and endothelial dysfunction are associated with cardiovascular risk factors and the development of atherosclerosis. Endocan is a marker of endothelial dysfunction, while obstructive sleep apnea is one of the causes of endothelial dysfunction. In this...

1 December 2016 in Acta Cardiologica
Verified
Journal Article
Closed access
MSMuhammet Hulusi Satilmisoglu
Muhammet Hulusi Satilmisoglu
MGMehmet Gul
Mehmet Gul
GYGunduz Yildiz
Gunduz Yildiz
OAOzgur Akgul
Ozgur Akgul
MKMehmet KAYA
Mehmet KAYA
AYAydin Yildirim
Aydin Yildirim
Objectives The aim of the study was to investigate the relationship between CHA2DS2-VASc score and in-hospital and long-term all-cause and cardiovascular mortality in patients with STEMI who underwent primary PCI. Methods In this retrospective study, 604 patients, admitted to the emergency department with a diagnosis of STEMI, were included. The study patients were divided into three risk groups according to CHA2DS2-VASc score: low-risk group (1 point), moderate-risk group (2 points), and high-risk group (3 points and higher), respectively. Results The mean follow-up time was 680 ± 286 days. In the high-risk group, the rates of in-hospital and long-term all-cause and cardiovascular mortality were higher than in the other groups. The Kaplan-Meier curves for the group with CHA2DS2-VASc scores > 2 indicated a significantly shorter long-term survival (P <0.001). In the receiver operating characteristic curve analysis, CHA2DS2-VASc scores > 2 were identified as an effective predictive cut-off point for all-cause mortality in STEMI (area under curve = 0.850, 95% confidence interval: 0.819–0.878, P< 0.001). CHA2DS2-VASc score > 2 yielded a sensitivity of 70.18% and a specificity of 83%. Conclusion The CHA2DS2-VASc is a simple and easily calculated score that provides an additional level of risk stratification beyond that provided by conventional risk scores in predicting in-hospital and long-term all-cause and cardiovascular mortality in STEMI.

1 January 2017 in Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology
Verified
Journal Article
Open access
SÖSinem Özyılmaz
Sinem Özyılmaz
SASat
Sat
HUHuseyin Uyarel
Huseyin Uyarel
OSOsman Akin Serdar
Osman Akin Serdar
Objective: The aim of this study was to determine the relationship between serum uric acid (UA) level and the predicted risk score for sudden cardiac death in 5 years (the HCM Risk-SCD), galectin-3 level, and positive fragmented QRS (fQRS) on electrocardiography (ECG) in patients with hypertrophic cardiomyopathy (HCM). Methods: This was a prospective, observational study. In all, 115 consecutive patients (age > 17 years) with HCM and 80 healthy participants were included in the study. The HCM Risk-SCD score (%), galectin-3 level, and fQRS on ECG were evaluated in all patients. Results: The serum UA, galectin-3 level, UA/Creatinine ratio, incidence of ventricular tachycardia (VT) and syncope, and some echocardiographic parameters were significantly higher in the patient group than in the control group (all p6%. Namely, HCM Risk-SCD >6%, UA: 6.71 +/- 1.29 mg/dL, HCM Risk-SCD <= 5.9%, UA: 5.84 +/- 1.39 mg/dL, p=0.001; fQRS(+), UA: 6.56 +/- 1.20 mg/dL, fQRS(-), UA: 5.63 +/- 1.49 mg/dL, p6.320 pg/mL, UA: 6.56 +/- 1.27 mg/dL, galectin-3 <= 6.310 pg/mL, p=0.016; left atrium anterior-posterior dimension (LAAPD) > 36 mm, UA: 6.31 +/- 1.33 mg/dL, LAAPD <36 mm, UA: 5.20 +/- 1.60 mg/dL, p=0.005; VT(+), UA: 6.83 +/- 1.19 mg/dL, VT(-), UA: 5.97 +/- 1.42 mg/dL, p=0.008; ICD(+), UA: 7.08 +/- 0.88 mg/dL, ICD(-), UA: 6.06 +/- 1.42 mg/dL, p=0.022; CPR(+), UA: 7.03 +/- 0.96 mg/dL, CPR(-), UA: 6.04 +/- 1.42 mg/dL, p=0.018. A statistically significant correlation was observed between UA and HCM Risk-SCD, galectin-3 level, LAAPD, and left ventricular (LV) mass (LVM) (r and p values, respectively: 0.355, <0.001; 0.297, 0.002; 0.309, 0.001; 0.276, 0.003. Conclusion: The serum UA level was significantly higher in patients with HCM compared with the control group. A high UA level was associated with a higher HCM Risk-SCD score, positive fQRS, higher galectin-3 level, greater LAAPD, VT incidence, and the need for ICD implantation and CPR in patients with HCM.

1 September 2018 in The Anatolian Journal of Cardiology
Verified
Journal Article
Open access
SÖSinem Özyılmaz
Sinem Özyılmaz
Objective: Micro T-wave alternans (MTWA) has been associated with poor arrhythmic prognosis in various cardiac disorders. The aim of this study was to assess the relationship between the presence of MTWA and the predicted 5-year risk of sudden cardiac death (HCM Risk-SCD) among patients with hypertrophic cardiomyopathy (HCM). Methods: A total of 117 consecutive HCM patients were included in this prospective observational study. Patients were divided into two groups, according to the presence [MTWA (+) group (n=44)] or absence [MTWA (-) group (n=73)] of MTWA on ambulatory (Holter) electrocardiography. Results: The risk of HCM Risk-SCD (%), the rate of high-risk patients (HCM Risk-ECG >6%), the requirement for cardiopulmonary resuscitation, and implanted cardioverter defibrillator therapy, the percentage of some clinical, echocardiographic, and Holter findings were all statistically higher in the MTWA (+) group than in the MTWA (-) group (all p4.9% was identified as an effective cutoff point in the MTWA (+) for HCM. The HCM Risk-SCD value of more than 4.9 yielded a sensitivity of 93.2% and a specificity of 84.5%. Conclusion: The presence of the MTWA on ambulatory electrocardiogram seems to be significantly associated with increasing percentages of the predicted HCM Risk-SCD score in patients with HCM. The MTWA was determined as an independent high-risk indicator for HCM Risk-SCD.